OBJECTIVE: When to start hepatitis C treatment in HIV/hepatitis C virus (HCV)-coinfected patients remains unresolved. Our objective was to determine if a baseline CD4 count >/=350 cells/mm predicts a sustained HCV response to pegylated interferon plus ribavirin. METHODS: We conducted a multicenter cohort study of HIV/HCV-coinfected patients treated for HIV in hospitals in Nice, Tourcoing, and Marseille (France). Sustained viral response (SVR) was defined as undetectable HCV RNA 24 weeks after treatment. The relation between CD4 cell count and SVR was examined separately for patients with HCV genotype 1 or non-1. RESULTS: One hundred seventy-five patients were included. In patients with HCV genotype 1, the rate of SVR was 13% and was not related to baseline CD4 cell count (odds ratio [OR] = 1.0, 95% confidence interval [CI]: 0.1 to 9.3). In patients with HCV genotype non-1, the rate of SVR was 46% and was not significantly increased by a baseline CD4 count >/=350 cells/mm (OR = 1.8, 95% CI: 0.6 to 5.9). CONCLUSIONS: Higher CD4 cell count at treatment initiation with pegylated interferon plus ribavirin did not improve treatment success probability, regardless of HCV genotype.
OBJECTIVE: When to start hepatitis C treatment in HIV/hepatitis C virus (HCV)-coinfectedpatients remains unresolved. Our objective was to determine if a baseline CD4 count >/=350 cells/mm predicts a sustained HCV response to pegylated interferon plus ribavirin. METHODS: We conducted a multicenter cohort study of HIV/HCV-coinfectedpatients treated for HIV in hospitals in Nice, Tourcoing, and Marseille (France). Sustained viral response (SVR) was defined as undetectable HCV RNA 24 weeks after treatment. The relation between CD4 cell count and SVR was examined separately for patients with HCV genotype 1 or non-1. RESULTS: One hundred seventy-five patients were included. In patients with HCV genotype 1, the rate of SVR was 13% and was not related to baseline CD4 cell count (odds ratio [OR] = 1.0, 95% confidence interval [CI]: 0.1 to 9.3). In patients with HCV genotype non-1, the rate of SVR was 46% and was not significantly increased by a baseline CD4 count >/=350 cells/mm (OR = 1.8, 95% CI: 0.6 to 5.9). CONCLUSIONS: Higher CD4 cell count at treatment initiation with pegylated interferon plus ribavirin did not improve treatment success probability, regardless of HCV genotype.
Authors: Annelies S Zinkernagel; Viktor von Wyl; Bruno Ledergerber; Martin Rickenbach; Hansjakob Furrer; Manuel Battegay; Bernard Hirschel; Philip E Tarr; Milos Opravil; Enos Bernasconi; Patrick Schmid; Rainer Weber Journal: Antivir Ther Date: 2006
Authors: R Agher; C Duvivier; C Katlama; Y Gérard; Y Yazdanpanah; E Billaud; T Jovelin; F Raffi; P Enel; I Poizot-Martin; P Puglièse; P Dellamonica; M Barone; L Cuzin; B Marchou Journal: Med Mal Infect Date: 2005 Jul-Aug Impact factor: 2.152
Authors: Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard Journal: Hepatology Date: 1999-10 Impact factor: 17.425
Authors: L Piroth; M Duong; C Quantin; M Abrahamowicz; R Michardiere; L S Aho; M Grappin; M Buisson; A Waldner; H Portier; P Chavanet Journal: AIDS Date: 1998-03-05 Impact factor: 4.177
Authors: Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren Journal: J Infect Dis Date: 2005-08-11 Impact factor: 5.226
Authors: Montserrat Laguno; Javier Murillas; José Luis Blanco; Esteban Martínez; Rosa Miquel; José M Sánchez-Tapias; Xavier Bargallo; Angeles García-Criado; Elisa de Lazzari; María Larrousse; Agathe León; Montserrat Loncá; Ana Milinkovic; Josep M Gatell; Josep Mallolas Journal: AIDS Date: 2004-09-03 Impact factor: 4.177
Authors: Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Jan van Lunzen; Julian Schulze Zur Wiesch; Claudia Beisel; Martin Heuer; Benjamin Otto; Johannes Jochum; Stefan Schmiedel; Sandra Hertling; Olaf Degen; Stefan Lüth Journal: AIDS Res Ther Date: 2014-07-01 Impact factor: 2.250